Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00265109 · ClinicalTrials.gov registry record · Phase 4
Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder
A Phase 4 study of Body Dysmorphic Disorder, sponsored by Butler Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT00265109 is a Phase 4 study of Body Dysmorphic Disorder that has completed, run by Butler Hospital. The registered enrollment target is 17 participants, below the 163-participant average among 3 other Body Dysmorphic Disorder trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00265109, a Phase 4 study of Body Dysmorphic Disorder, has completed, sponsored by Butler Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the usefulness of a medication (Levetiracetam) for people with body dysmorphic disorder.
Conditions Studied
Interventions
- DRUG Levetiracetam
Study Locations (1)
Rhode Island
- Rhode Island Hospital Body Dysmorphic Disorder Program - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2004-12 |
| Est. Completion | 2008-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00265109
The ClinicalTrials.gov registry entry for NCT00265109 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 163-participant average among 3 other Body Dysmorphic Disorder trials with a reported enrollment target (90% lower). The listed sponsor is Butler Hospital, which has 103 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Body Dysmorphic Disorder appearing as the primary indexed condition, and to 1 intervention - of which Levetiracetam is the first listed.
NCT00265109 reports 1 study location spanning 1 distinct geographic area - top geographies include Rhode Island.
Frequently Asked Questions
What is clinical trial NCT00265109 about?
NCT00265109 is a clinical study titled "Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder". The purpose of this study is to assess the usefulness of a medication (Levetiracetam) for people with body dysmorphic disorder.
What is the current status of trial NCT00265109?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 17 participants. The study started on 2004-12. Estimated completion is 2008-01.
What conditions does trial NCT00265109 study?
This clinical trial studies the following conditions: Body Dysmorphic Disorder.
What interventions are being tested in trial NCT00265109?
The interventions under investigation include: Levetiracetam (DRUG).
Who is sponsoring clinical trial NCT00265109?
This trial is sponsored by Butler Hospital, which has 103 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00265109 being conducted?
This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Body Dysmorphic Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Individual Factors of CBT Underlying Success
RECRUITING · NA
-
Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals
ACTIVE NOT RECRUITING · NA
-
Waitlist-Control Trial of Smartphone Cognitive Behavioral Therapy (CBT) for Body Dysmorphic Disorder (BDD)
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.